Abstracts tagged "Fc receptors and rheumatoid arthritis (RA)"

Abstract Number: 536 • 2015 ACR/ARHP Annual Meeting
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By TNF-Alpha and IL-6 Axis in Accompany with Disease Activity in Rheumatoid Arthritis Patients
Masako Tsukamoto¹, Katsuya Suzuki², Noriyuki Seta³, Keiko Yoshimoto², Kunihiro Yamaoka² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan
Background/Purpose: Recently, three different subsets of circulating monocytes: CD14brightCD16- (classical), CD14brightCD16+ (intermediate) and CD14dimCD16+ (nonclassical) monocytes have been defined. It has been reported that circulating…
Abstract Number: 2348 • 2014 ACR/ARHP Annual Meeting
Activatory Fc Gamma Receptor IV Plays a Crucial Role in Pathogenesis of Experimental Immune Complex Mediated Chronic Arthritis
Irene Di Ceglie¹, Arjen Blom¹, Sjef Verbeek², Peter van der Kraan³, Wim van den Berg¹ and Peter L. van Lent¹, ¹Experimental Rheumatology, Experimental Rheumatology, Radboud University, Nijmegen, Netherlands, ²Human Genetic, Human Genetic, Leiden University Medical Center, Leiden, Netherlands, ³Experimental Rheumatology, Radboud University, Nijmegen, Netherlands
Background/Purpose Rheumatoid arthritis is characterized by Immune complex dependent chronic joint inflammation and severe cartilage and bone destruction. Earlier we found that in the absence…
Abstract Number: 2420 • 2013 ACR/ARHP Annual Meeting
Pleiotropic Roles Of Fcγ Receptors Upregulated On Circulating Monocytes In Rheumatoid Arthritis Patients
Masako Tsukamoto¹, Katsuya Suzuki², Keiko Yoshimoto², Hideto Kameda² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: We have previously demonstrated that Fc gamma receptor(FcgR)II) and CD64(FcgRI) molecules on CD14+ cells were measured by flow cytometry. FcgR IIIa, anti-CD16 antibody(1D3) which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].